1. Scrip

Quick Listen: Scrip's Five Must-Know Things

 
• By Ian Haydock

In this week's edition: Lilly plans tirzepatide ads; Pfizer’s Bourla defends strategy; expert views from BioFuture; China retains attractions for some; and AbbVie’s Aliada acquisition.

Scrip Five Must Know Things
weekly audio roundup of selected content from Scrip's global team

Join us for an audio catch-up on the major events in the global biopharma industry over the past business week, as reported by Scrip‘s global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 1 November 2024, including: Lilly plans DTC tirzepatide ads; Pfizer’s Bourla defends strategy; expert views from BioFuture; China retains attractions for some; and AbbVie’s Aliada acquisition.

This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

Lilly Plans Mounjaro/Zepbound DTC Ads To Stoke Brand Awareness

Pfizer’s Bourla Defends Strategy In The Wake Of Starboard’s Activist Investment

PBMs, FTC and IRA: Experts Tackle Pharma’s Tough Acronyms At BioFuture Conference

China Innovation, Large Market Continue To Lure Foreign Investment

AbbVie Adds Alzheimer’s Opportunity With $1.4bn Aliada Buy

More from Scrip

ASCO Preview: Data From Regeneron, J&J/Legend And Others In Hematology

 
• By Alaric DeArment

With the American Society of Clinical Oncology meeting kicking off on 30 May, Scrip will follow the latest in blood cancers, including Regeneron’s linvoseltamab in multiple myeloma and Merck’s ADC zilovertamab vedotin in DLBCL.

Finance Watch: Public Company Fundraising Sank Across The Board In Q1

 
• By Mandy Jackson

Public Company Edition: Biomedtracker’s first quarter 2025 financing report shows follow-on offerings, IPOs and PIPEs fell sharply from Q1 of 2024. In recent transactions, Teva sold $2.3bn worth of notes, Regenxbio executed a royalty deal for up to $250m and Aura’s FOPO grossed $75m.

Deal Watch: QurAlis Targets Fragile-X Syndrome In Deals With Quiver, UMass

 
• By Joseph Haas

Plus the end of Sanofi’s six-target alliance with IGM, OmniAb’s deals with Veraxa and Angelini, alliances involving Skye/Arecor, Genprex/UTHealth Houston and more.

GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod

 
• By Kevin Grogan

The UK major's asthma drug gets a key expanded approval.

More from Scrip's Five Must-Know Things

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Trump’s drug pricing executive order; J&J says taxes, not tariffs, influence US manufacturing; Pfizer discontinuation sparks M&A speculation; US tariffs and manufacturing concentration; and tariffs’ pressures on pharma’s complex supply chain.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Trump’s tariff rollercoaster; regulatory, economic uncertainties hang over Q1 earnings; IPOs rise in Q1 but may slow; Chinese deal-making matures; and AstraZeneca talks about Chinese innovation.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: pharma dodges tariffs for now; Marks’s departure from FDA rattles industry; Phase 2b win for AstraZeneca’s oral PCSK9; Hengrui renews global Phase 3 push; and Novo’s new cardio results for semaglutide.